14-day Premium Trial Subscription Try For FreeGet Free

Range Low Price High Price Comment
30 days $103.63 $117.41 Wednesday, 29th Nov 2023 NBIX stock ended at $113.54. This is 0.62% more than the trading day before Tuesday, 28th Nov 2023. During the day the stock fluctuated 3.01% from a day low at $110.81 to a day high of $114.15.
90 days $103.63 $119.28
52 weeks $89.04 $129.29

Historical Neurocrine Biosciences prices

Date Open High Low Close Volume
2023-11-29 $113.17 $114.15 $110.81 $113.54 539 371
2023-11-28 $112.60 $113.43 $111.81 $112.84 618 541
2023-11-27 $111.12 $113.23 $110.52 $113.02 724 342
2023-11-24 $110.99 $112.28 $110.63 $112.17 220 514
2023-11-22 $110.48 $111.78 $109.77 $110.98 552 302
2023-11-21 $109.89 $111.27 $108.63 $109.61 644 135
2023-11-20 $108.14 $110.09 $108.14 $109.43 471 235
2023-11-17 $109.03 $109.64 $108.29 $108.94 508 175
2023-11-16 $110.55 $110.55 $107.84 $108.77 632 030
2023-11-15 $112.05 $113.19 $110.61 $110.71 542 581
2023-11-14 $112.00 $114.52 $111.77 $112.38 908 415
2023-11-13 $106.85 $110.37 $106.85 $110.25 497 345
2023-11-10 $106.30 $108.41 $103.63 $107.17 1 545 548
2023-11-09 $115.82 $115.82 $111.75 $112.15 489 654
2023-11-08 $116.68 $117.41 $114.70 $115.39 483 243
2023-11-07 $114.52 $117.35 $113.69 $116.68 777 807
2023-11-06 $112.64 $114.42 $112.59 $114.01 523 236
2023-11-03 $114.63 $114.81 $112.37 $112.44 512 572
2023-11-02 $112.66 $113.84 $111.37 $113.39 658 801
2023-11-01 $110.89 $111.81 $108.23 $111.54 825 509
2023-10-31 $106.48 $111.43 $106.48 $110.94 1 381 299
2023-10-30 $106.76 $107.93 $106.59 $107.13 745 460
2023-10-27 $107.25 $108.28 $106.01 $106.07 492 424
2023-10-26 $108.12 $109.31 $107.52 $107.92 560 018
2023-10-25 $108.27 $109.00 $106.95 $108.23 442 710
Click to get the best stock tips daily for free!

About Neurocrine Biosciences

Neurocrine Biosciences Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON... NBIX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT